営業利益率
2005年以降
計算
Gilead Sciences Inc.、営業利益率、長期トレンド計算
| 営業利益率 | = | 100 | × | 営業利益(損失)1 | ÷ | 製品販売1 | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | 5.81% | = | 100 | × | 1,662) | ÷ | 28,610) |
| 2023/12/31 | 28.24% | = | 100 | × | 7,605) | ÷ | 26,934) |
| 2022/12/31 | 27.17% | = | 100 | × | 7,330) | ÷ | 26,982) |
| 2021/12/31 | 36.72% | = | 100 | × | 9,918) | ÷ | 27,008) |
| 2020/12/31 | 16.72% | = | 100 | × | 4,071) | ÷ | 24,355) |
| 2019/12/31 | 19.38% | = | 100 | × | 4,287) | ÷ | 22,119) |
| 2018/12/31 | 37.83% | = | 100 | × | 8,200) | ÷ | 21,677) |
| 2017/12/31 | 55.04% | = | 100 | × | 14,124) | ÷ | 25,662) |
| 2016/12/31 | 58.87% | = | 100 | × | 17,633) | ÷ | 29,953) |
| 2015/12/31 | 69.03% | = | 100 | × | 22,193) | ÷ | 32,151) |
| 2014/12/31 | 62.37% | = | 100 | × | 15,265) | ÷ | 24,474) |
| 2013/12/31 | 41.87% | = | 100 | × | 4,524) | ÷ | 10,804) |
| 2012/12/31 | 42.67% | = | 100 | × | 4,010) | ÷ | 9,398) |
| 2011/12/31 | 46.77% | = | 100 | × | 3,790) | ÷ | 8,102) |
| 2010/12/31 | 53.62% | = | 100 | × | 3,962) | ÷ | 7,390) |
| 2009/12/31 | 54.55% | = | 100 | × | 3,529) | ÷ | 6,469) |
| 2008/12/31 | 52.68% | = | 100 | × | 2,679) | ÷ | 5,085) |
| 2007/12/31 | 57.98% | = | 100 | × | 2,165) | ÷ | 3,733) |
| 2006/12/31 | -29.32% | = | 100 | × | (759) | ÷ | 2,588) |
| 2005/12/31 | 61.41% | = | 100 | × | 1,111) | ÷ | 1,809) |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
1 百万米ドル
競合他社との比較
Gilead Sciences Inc.、営業利益率、長期トレンド、競合他社との比較
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | 5.81% | 16.22% | 22.66% | 20.37% | 28.10% | 17.11% | -2.11% |
| 2023/12/31 | 28.24% | 23.49% | 29.35% | 21.77% | 30.85% | 16.00% | 38.83% |
| 2022/12/31 | 27.17% | 31.21% | 38.57% | 27.61% | 38.93% | 18.69% | 48.23% |
| 2021/12/31 | 36.72% | 31.89% | 31.44% | 25.35% | 55.67% | 25.57% | 36.73% |
| 2020/12/31 | 16.72% | 24.81% | 37.70% | 18.99% | 42.09% | 24.19% | 46.03% |
| 2019/12/31 | 19.38% | 39.03% | 43.57% | 18.25% | 28.10% | 17.99% | 28.77% |
| 2018/12/31 | 37.83% | 19.49% | 45.55% | 17.11% | 37.77% | 15.53% | 20.84% |
| 2017/12/31 | 55.04% | 33.99% | 45.76% | 16.48% | 35.41% | 14.19% | 4.95% |
| 2016/12/31 | 58.87% | 36.60% | 44.74% | 16.29% | 27.38% | 13.40% | 0.58% |
| 2015/12/31 | 69.03% | 32.97% | 40.44% | 16.87% | 30.51% | 13.77% | -45.23% |
| 2014/12/31 | 62.37% | 17.09% | 32.03% | 17.23% | 29.74% | 14.82% | -119.30% |
| 2013/12/31 | 41.87% | 30.14% | 32.25% | 17.13% | 36.11% | 12.30% | -74.54% |
| 2012/12/31 | 42.67% | 31.65% | 33.52% | 17.33% | 33.20% | 11.85% | 0.15% |
| 2011/12/31 | 46.77% | — | 28.19% | 16.27% | -46.02% | 10.62% | 8.07% |
| 2010/12/31 | 53.62% | — | 37.82% | 16.41% | -21.23% | 11.72% | -485.51% |
| 2009/12/31 | 54.55% | — | 38.37% | 13.79% | -19.54% | 10.38% | -602.63% |
| 2008/12/31 | 52.68% | — | 35.50% | 14.72% | -37.67% | 11.71% | -263.65% |
| 2007/12/31 | 57.98% | — | 27.81% | 15.79% | -91.55% | 10.00% | -210.94% |
| 2006/12/31 | -29.32% | — | 27.71% | 15.82% | -169.68% | 6.38% | -105.86% |
| 2005/12/31 | 61.41% | — | 40.33% | 15.84% | -187.97% | 10.01% | -93.15% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).